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GENERAL INTRODUCTION 
Platelets are small cytoplasmic fragments released from 
megakaryocytes and found in relatively large numbers in the 
peripheral blood. Platelets function in hemostasis, help 
maintain vascular integrity, enhance coagulation and 
participate in the inflammatory response.^ 
Platelet disorders can be classified as inherited or 
acquired and include thrombocytopenia, thrombocytosis, 
thrombasthenia, idiopathic thrombopathies and thromboembolic 
disease. Von Willebrand disease (vWD), which is a clinical 
syndrome secondary to a deficiency in functional von 
Willebrand factor (vWf), has the clinical presentation of a 
2 platelet disorder. 
The domestic pig fSus scTOfa domesticus) is a well 
3 . 4 
recognized model of cardiovascular and bleeding disorders 
5 including immune-mediated neonatal and viral-induced 
thrombocytopenias,^ ^ bacterial-induced thrombotic 
9-12 13 disease, hereditary thrombopathy and von Willebrand 
disease. 
The objectives of these studies were 1) to determine 
selected age-related normal values for platelet numbers and 
platelet aggregation curves in pigs, 2) to examine the 
effects of oral aspirin, a potent inhibitor of arachidonic 
acid metabolism, on porcine platelet function and 3) to 
2 
determine if aspirin pretreatment would modify the effects 
of intravenous collagen infusions in anesthetized piglets. 
Explanation of the dissertation format 
This dissertation is presented in the alternative 
format as 3 manuscripts written in the style of the American 
Journal of Veterinary Research. A review of the literature 
precedes the first manuscript. The first manuscript has 
been submitted to the American Journal of Veterinary 
Research. A general summary follows the last manuscript. 
Each manuscript has a list of references while literature 
cited in the general introduction, literature review and 
general summary appears at the end of the dissertation. In 
addition, three appendices offer additional research 
information pertinent to the dissertation but not Included 
in the manuscripts. 
The Ph.D. candidate, James A. Matthews, was the 
principal investigator in each of the experiments and is 
listed as the first author on each of the manuscripts. Dr. 
Arlo E. Ledet was instrumental in the planning and review of 
each of the experiments. He also facilitated the use of the 
veterinary clinical pathology laboratory at the Iowa state 
University Veterinary College. Research pigs were 
generously provided by Dr. Lawrence E. Evans. Dr. Evans 
also was generous with his time and provided invaluable 
3  
instruction concerning animal handling and blood sampling 
techniques. The last experiment was performed in Dr. 
Richard L. Engen's research laboratory under his direct 
supervision and with his help. 
4 
LITERATURE REVIEW 
There is a large body of information concerning 
platelets but only a relatively small number of studies 
using porcine platelets- Several explanations for this 
discrepancy can be advanced. The most obvious reason is 
that research opportunities follow funding and human 
diseases have priority over diseases of swine. Furthermore, 
human platelets are readily available from both volunteers 
and blood banks. Platelet-rich samples can be drawn 
repeatedly from the same donor with only a minimum of 
discomfort and at very small risk. Additionally human 
subjects apparently readily agree to ingest drugs (i.e., 
aspirin, indomethacin and alcohol) that affect platelet 
function. 
Pigs are large malodorous vociferous animals that can 
violently resist blood collection. As research animals they 
require feed, water, housing and occasional veterinary care. 
In addition pigs are generally more expensive than other 
common laboratory animals (rabbits, rats, cats, guinea pigs 
and even mongrel dogs). 
Pigs, however, share many functional and anatomical 
similarities with man. Atherosclerosis and von Willebrand 
disease are two naturally occurring diseases in pigs which 
3 ,4 parallel human diseases. 
5 
The understanding of porcine platelet physiology and 
its role in the pathogenesis of swine diseases has intrinsic 
as well as possible economic value. The United States 
Department of Agriculture, in AcrrlcultuTe Statistics 1986, 
estimated the total value of 1985 U.S. hog production at 
8.85 billion dollars. This represented a total U.S. herd 
size of 52.3 million hogs and pigs: less than 8% of world 
hog numbers. 
Platelet numheis 
Megakaryocytes, large granular cells containing a 
single multilobed nucleus, are found primarily in the bone 
marrow although they also occur in the lung and less 
frequently in the spleen, liver and lymph nodes. Platelets 
are cytoplasmic fragments of megakaryocytes. Thrombopoiesis 
is regulated by thrombopoietin which in turn is controlled 
by the circulating platelet mass. In health it is estimated 
that approximately one-third of an animal's platelet mass is 
sequestered in the spleen where they can be rapidly 
mobilized. 
Reported blood platelet counts in pigs vary 
17-22 
markedly. A portion of the difference may be breed 
related differences. The breeds represented in these 
17 18 
reports include the White/Wessex cross, Chester White, 
B e r k s h i r e , H a m p s h i r e s ^ ^  a n d  D u r o c ^ ^  b r e e d s ,  N o r w e g i a n ^ ^  
21 2 2 
and Nigerian pigs and miniature swine. 
6 
Platelet counts in the pig may also be age dependent. 
While the cited reports represent pigs between 1 day^^ 
2 2 
and 42 months of age a general pattern is evident. Mean 
blood platelet counts rise from birth, peak at 10 days to 2 
weeks of age and then gradually decrease from 5 weeks of age 
down to stable adult values by 9 months. 
Some properties of porcine platelets 
Porcine platelets are very similar to platelets in 
other species including man. Porcine platelets are small (1 
to 4 micron, 6.1 to 8.7 fl)^^'^^ nonnucleated cell fragments 
that appear granular in Romanowsky stained blood smears 
examined by light microscopy. 
Transmission electron microscopic examination of 
platelets has revealed two major types of granules: dense 
granules and a granules. Porcine platelet dense granules 
contain adenosine diphosphate (ADP) and adenosine 
triphosphate (ATP), serotonin (5-hydroxytryptamine) and the 
bivalent cations magnesium and calcium.The blood 
platelet nucleotide content and the ATP:ADP ratio of porcine 
2 8 2 9 platelets is very close to that of man. ' The a granule 
is generally more numerous than the dense granule and 
contains proteins with antiheparin activity, von Willebrand 
factor, fibrinogen, fibronectin and platelet derived growth 
factor.^^ The heparin neutralizing ability of porcine 
7 
platelets is reportedly greater than that of human 
p l a t e l e t s . T w o  p o r c i n e  p l a t e l e t  h e p a r i n - b i n d i n g  p r o t e i n s ,  
porcine platelet factor 4 and porcine platelet basic protein 
have been identified. The amino acid composition of porcine 
platelet factor 4 is similar to human platelet factor 4 and 
the two proteins have significant immunologic cross 
reactivity. Porcine platelet basic protein shares 
immunologic reactivity with two human platelet proteins that 
bind to heparin with low affinity; ^-thromboglobulin and 
3 2 low affinity platelet factor 4. The porcine platelet 
membrane contains 3 major glycoproteins which are similar to 
3 3 the 3 major glycoproteins of the human platelet membrane. 
Platelets, in all mammalian species, respond 
sequentially to various stimuli, or agonists, by first 
changing shape and then aggregating.^® Aggregation can be 
monitored in the laboratory by turbidometric methods as a 
3 4 
way of testing platelet function. Comparative studies into 
platelet aggregation have found that the extent and pattern 
of aggregation induced by an agonist varies markedly between 
species.This variance is further confounded by 
4 2,43 
variations within species, by variations due to 
44-45 
age and, most remarkably, by variations in the type of 
response•from a single platelet rich plasma (PRP) sample to 
4 7 different concentrations of a single agonist. 
8 
Quantitative turbidometric studies of platelet 
aggregation began with a 1962 report by Born using "pig's 
g 
plasma... containing 3.5 x 10 platelets/ml". Born also 
noted that platelet aggregation could occur without clot 
48 formation. Later it was shown that porcine platelet 
aggregation is dependent on the presence of divalent cations 
4 9.50 
and fibrinogen, ' 
Platelet aggregation in man may occur through the 
activation of 2 or 3 related pathways which are triggered by 
a variety of stimuli.The mechanism of platelet 
aggregation in animals is not as well defined. Porcine 
platelets will aggregate when exposed to many of the same 
agonists that trigger human platelet aggregation but, as 
previously suggested, there are some major differences. 
AD? stimulates either reversible monophasic or, with 
higher concentrations, irreversible biphasic platelet 
4 7 
aggregation in human PRP. ADP stimulates only reversible 
3 8 4 0 
monophasic platelet aggregation in porcine PRP. Meyers 
incorrectly states that this aggregation is irreversible.^^ 
Platelets from both humans and pigs are inhibited by prior 
incubation with adenosine, adenosine monophosphate (AMP) or 
prostaglandin 26,37,39,40 human platelets will 
respond with biphasic irreversible aggregation to 
epinephrine.Porcine platelets neither respond to 
9 
epinephrine nor does epinephrine potentiate their response 
to other agonists the way it does in human and canine 
PRP.^^'^^ Serotonin, however, potentiates ADP-induced 
3 9 
aggregation in man and pigs. Collagen and low 
concentration thrombin induce irreversible platelet 
aggregation in both man and pigs.^^'^^'^^ Arachidonic acid 
concentrations adequate to induce irreversible platelet 
aggregation in human FRF only induce shape change in porcine 
p l a t e l e t s . T h e  p i g  p l a t e l e t ,  i n  t h i s  i n s t a n c e ,  m o r e  
5 3 
resembles the rat than the human platelet. Finally, snake 
venom coagglutinin causes von Willebrand factor dependent 
5 4,55 platelet aggregation in man and in pigs. 
Platelet related disorders in piers 
Von Willebrand disease (vWD) is a spontaneously 
occurring disease which affects dogs, man and 
pigs.^^'^^'^^ In man, vWD occurs as either a quantitative 
decrease or an abnormality in von Willebrand factor 
(vwf)^^ , a large multimeric molecule which is also known 
as factor VIII:related antigen (VIIIR:Ag).This factor is 
synthesized by endothelial cells®^ and megakaryocytes^^ 
and can be immunologically localized to plasma, platelets, 
megakaryocytes and endothelial cells.Although vWD 
is not a primary defect of platelets vWf is necessary for 
platelet adherence to the subendothelium and the formation 
10 
71-73 
O f  the primary hemostatic plug. Porcine vWD is 
transmitted as an autosomal recessive trait.The major 
focus of porcine vWD research has been directed at the role 
of the platelet-blood vessel interaction in the development 
7 4 - 8 0  
of atherosclerosis. Pigs with severe vWD are resistant 
to diet induced and spontaneous atherosclerosis due to a 
reduced interaction between platelets and damaged 
endothelial surfaces. In other words, the normal platelet 
mediated vessel repair process may be a "trigger" for the 
8 0 development of atherosclerosis. Born has stated, in no 
uncertain terms, that platelets do not contribute to 
atherosclerosis by damaging normal arterial endothelial 
81 
surfaces. 
An unusual bleeding disease in pigs has recently been 
described. Those affected pigs are part of a colony of vWD 
research pigs at the Mayo clinic research facilities. The 
clinical signs (bleeding times markedly increased), reduced 
collagen stimulated platelet aggregation response and a 
decrease in platelet dense granule numbers and contents 
(ADP, ATP and serotonin) suggest a platelet storage pool 
deficiency. This thrombopathy is believed to be an 
inherited platelet defect transmitted in an autosomal 
13 
recessive manner. 
11 
Neonatal thrombocytopenic purpura occurs in piglets of 
multiparous sows who have been immunized by fetal antigens 
from the boar. The primary clinical signs are petechial 
hemorrhages, excessive bleeding times and extensive 
5 bruising. 
The thrombocytopenia associated with African swine 
fever may also be immune related. While the exact mechanism 
is still unclear, pigs innoculated with an African swine 
fever isolate became thrombocytopenic on days 6 to 8 post 
innoculation concurrent with the appearance in serum of 
8 
antiviral antibodies. 
Iron deficiency in piglets is reported to cause a 
thrombocytosis. Copper deficiency apparently does not 
affect platelet numbers. 
Thrombotic disease in connection with various bacterial 
infections is very probably the most common platelet related 
disorder found in pigs. Both renal and pulmonary thrombi 
are described with induced Salmonella, Hemophilus and 
Eryslpelothrix infections in pigs.®"^^ 
Morphologic and functional platelet changes have been 
described in porcine stress syndrome susceptible pigs. The 
significance of these changes, a dilation of the open 
canalicular system and a decreased aspirin inhibition of in 
vitro collagen-induced platelet aggregation, and their 
relationship to the syndrome are not known. 
12 
Thromboembolic pulmonary disease, resembling adult 
respiratory distress syndrome (ARDS) in people, has been 
induced in anesthetized pigs by shooting them in the hind 
leg with a rifle. Pulmonary trapping of platelets and 
fibrin was monitored by external detection of 
radioactivity.^^ 
Platelet function is impaired in alcoholic patients. 
Anesthetized pigs given ethanol through a gastric tube, 
however, had increased numbers of circulating 
microaggregates in the vena cava and in the portal vein both 
before and after standardized trauma (200 blows with a 
rubber hammer on the inside of each thigh). This trauma was 
not lethal to control pigs while 6 of 7 pigs pretreated with 
alcohol died. The authors of this report felt that the 
mortality followed an alcohol suppressed ability to maintain 
circulating volume rather than increased pulmonary 
microaggregate trapping.®® 
Aspirin, azachldonic acid and ylcrs 
Aspirin, acetylsalicylic acid, is a nonsteroidal anti­
inflammatory drug that inhibits the cyclo-oxygenase enzyme 
in platelets.This inhibits the formation of 
thromboxane from membrane derived arachidonic acid for the 
89-91 life time of the platelet. An excellent review of the 
effects of aspirin on platelet physiology has been recently 
92 
published. 
13 
Aspirin also inhibits the formation of prostacyclin 
91 from arachidonic acid by endothelial cells. Although 
endothelial cyclo-oxygenase activity is rapidly restored 
9 3 
after withdrawal of aspirin there has been concern that 
high dose aspirin therapy may be thrombogenic. one study in 
man reported that a single low dose oral aspirin treatment 
(0.3 g) increased the bleeding time when compared against 
both the control and the high dose (3.9 g) treatment 
94 groups. 
The concept that high dose aspirin may be thrombogenic 
has been attacked from two directions. First, the role of 
prostacyclin in the maintenance of vascular patency has not 
been established. Arthritis patients at the Mayo Clinic on 
prolonged high dose aspirin therapy did not have an 
increased rate of thrombosis. On the contrary, the aspirin 
treated male group had a decreased incidence of thrombotic 
95 
events. The second stronger argument suggests that 
salicylic acid, the breakdown product of acetylsalicylic 
acid, interferes with the platelet inhibitory effects of 
aspirin. In man salicylate has a longer plasma half-life 
(4-5 hours) than aspirin (0.25-0.33 hours) so a dose of 
aspirin may partially inhibit the effects of a subsequent 
96 
aspirin dose. 
14 
Interestingly, while salicylate does not suppress 
96 
arachidonic acid-induced platelet aggregation it is still 
9 7 
a potent anti-inflammatory drug. Apparently salicylate, 
like aspirin, exhibits its anti-inflammatory action by 
9 8 inhibiting prostaglandin E2 synthesis. 
While aspirin has been used in a wide variety of 
inflammatory and thrombotic diseases in man and 
91-93.99-101 
animals it has had very limited use in the pig. 
Aspirin has been reported to reduce the incidence and 
severity of atherosclerotic lesions in pigs following 
induced intravascular trauma (repeated balloonings) and in 
pigs fed atherogenic hyperlipidemic diets.Similarly 
platelet deposition and mural thrombus formation following 
balloon angioplasty was reduced in pigs pretreated with 
aspirin alone or in combination with another drug. 
Aspirin, 20 mg/kg, administered intravenously 15 
minutes before challenge with heterologous erythrocytes 
prevented severe shock reactions in 5 sensitized pigs while 
severe shock reactions, usually fatal, occurred in 9 of 14 
untreated controls. 
Unfortunately oral aspirin has been shown to cause 
severe gastric mucosal damage in pigs given 30 mg/kg for 10 
107 days. The development of the mucosal lesions coincided 
with the inhibition of mucosal prostaglandin and 
10 8 prostacyclin production. 
15 
EXPERIMENT I 
16 
The effect of age on in vitro porcine platelet aggregation 
James A. Matthews, D.V.M., M.S. 
Arlo E. Ledet, D.V.M., Ph.D. 
Lawrence E. Evans, D.V.M., Ph.D. 
From the Department of Veterinary Pathology (Matthews, 
Ledet) and the Department of Veterinary Clinical Sciences 
(Evans), College of Veterinary Medicine, Iowa State 
University, Ames, IA 50011. 
Supported by the Iowa State University Research Grants 
Program. 
This report represents a portion of a dissertation 
presented by the senior author to the Graduate College of 
Iowa State University in partial fulfillment of the 
requirements for the Ph.D. degree. 
The authors thank Sarah Nusser for performing the 
statistical analysis and Dr. K. M. Meyers for his review of 
the manuscript. 
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SUMMARY 
Platelet counts in whole blood and platelet aggregation 
responses to adenosine diphosphate (ADP), collagen and 
sodium arachidonate were measured in three age groups of 
pigs: neonates, 3 to 6 week old piglets and adult gilts and 
sows. Mean platelet counts were significantly (P<0.05) 
higher in the 3 to 6 week old group than in the neonates 
which were also significantly higher than the mean adult 
platelet count. Neonatal platelet response to ADP and 
collagen was similar to the adult platelet response. Sodium 
arachidonate induced reversible platelet aggregation in 8 of 
20 neonates tested but induced only irreversible aggregation 
in the adult pig platelet samples. The 3 to 5 week old 
piglet platelet showed the greatest aggregation response to 
ADP and collagen but a slightly decreased aggregation with 
sodium arachidonate when compared with the adult pigs. 
18 
INTRODUCTION 
Platelet aggregation can be induced in the laboratory 
by specific platelet aggregation agents and recorded with a 
platelet aggregometer. The aggregation tracing represents 
an increasing transmittance of light as a cloudy suspension 
of platelets in plasma becomes a clear plasma containing a 
few large platelet aggregates. Analysis of this tracing can 
be use to quantitate the delay between the addition of an 
aggregating agent and the first measurable increase in 
transmittance (the lag phase), the rate of change in 
transmittance as aggregation progresses (the slope) and the 
maximal percent transmittance (maximal aggregation). The 
overall pattern of the tracing can indicate if the induced 
aggregation represents primary aggregation, secondary 
aggregation or a combined diphasic aggregation.^ 
The purpose of the present study was to examine the 
response of the porcine•platelet at three different ages 
which are potentially associated with increased hemostatic 
stress: neonatal (birth), 3 to 6 weeks of age (castration) 
and adulthood (parturition) . 
19 
MATERIALS AND METHODS 
Pigs-Sixty healthy Hampshire-Landrace-Duroc cross pigs, 
20 in each age group, were used. Neonates, 10 of each sex, 
were bled at 2 days of age. Twenty male piglets were bled 
between 3 and 6 weeks of age. Twenty mature gilts and sows 
formed the adult group. All pigs were pseudorabies and 
rhinitis free and maintained indoors at Iowa State 
University. The pigs were drug free prior to and during 
sampling. Piglets had received a single subcutaneous 
injection of iron dextran at 3 days of age. 
Platelet aggregation-Blood from the anterior vena cava 
(sows) or the periorbital venous sheath (neonates and 
piglets) was collected from physically restrained 
unanesthetized pigs into plastic syringes or plastic tubes 
containing 3.8% sodium citrate at a ratio of 9 volumes of 
blood to 1 volume of anticoagulant. 
Platelets were counted manually using a dilution 
system^ and light microscopy. 
Undiluted citrated blood was transferred to capped 
polypropylene centrifuge tubes and centrifuged (600 x g for 
2.0 min at 20° C) to obtain platelet rich plasma (PRP). The 
PRP was diluted with platelet poor plasma (PPP:1300 x g for 
20 min at 20" C) to obtain a platelet concentration of 
20  
approximately 200,000 platelets/jUl • This adjusted PRP was 
held at room temperature in tightly capped polystyrene tubes 
until testing. All tests were completed within 3 hours of 
sample collection. 
Platelet aggregations were performed in adjusted PRP 
2 
according to the turbidometric method of Born. Samples were 
maintained at 37° C for 3 min before the addition of the 
Id c 
aggregating agent. Adenosine diphosphate (ADP), collagen 
and sodium arachidonate^ were used as the aggregating 
agents. Adenosine diphosphate was used as a 200 mM stock 
solution giving a final concentration of ADP in the PRP of 
20 mM. Collagen from bovine tendon was used in a final 
concentration of 10.0 jug/ml. Sodium arachidonate was 
diluted with normal saline to a final concentration of 6.9 
mM. Platelet aggregation was recorded over a 5 minute 
period using a multichannel platelet aggregometer^. 
Measured parameters were the maximum % aggregation 
where PRP was set as 0% transmission and PPP was 100% 
transmission and the slope as the initial % change in 
transmittance per minute. The lag time between the addition 
of collagen and the point in which measurable aggregation 
occurred was also measured. In addition, aggregation curves 
were examined for overall pattern. 
21 
Plasma cholesterol values were determined on 5 pigs 
from each age group using a routine spectrophotometric 
technique*^. 
All aggregations were performed in duplicate and the 
mean result was calculated. Group data are expressed as the 
mean ± the standard error of the mean (SEM). An analysis of 
variance (ANOVA)® was performed to detect age differences in 
the measured aggregation parameters for all three 
aggregating agents. When the ANOVA indicated that an age 
effect was present least significant differences were 
calculated to determine which means were significantly 
different from one another. A significance level of 0.05 
was maintained throughout the study. 
22 
RESULTS 
There was considerable overlap in the range of the 
platelet counts between the 3 age groups however mean 
platelet counts rose significantly from 2 days of age to 3 
to 5 weeks of age then subsided to the adult values (Table 
1) . 
Adult pig platelets aggregated with sodium 
arachidonate, collagen and, to a lesser degree, ADP. 
Addition of sodium arachidonate resulted in either a single 
or diphasic curve representing an irreversible aggregation. 
Collagen-induced a single wave of irreversible aggregation 
while ADP caused a spontaneously reversible aggregation (Fig 
1) . 
Neonatal piglet platelet maximum aggregations induced 
by collagen and ADP were similar to adult porcine platelet 
responses (Table 2). Sodium arachidonate, however, induced 
an attenuated response in 8 (5 females and 3 males) of the 
20 neonatal porcine samples with a single wave of reversible 
aggregation (Fig 2). A biphasic response to sodium 
arachidonate was not observed in this age group. 
Platelet samples obtained from the 3 to 6 week old 
piglets responded at or above adult values with the single 
exception of a decreased lag phase following the addition of 
23 
TABLE 1. Normal porcine platelet numbers in sodium citrate 
anticoagulated whole blood (9 parts blood;l part 
3.8% sodium citrate) 
3 * 
Platelets x 10 /jul Range 
Groupé n (mean±SEM^) (platelets x IO^/mD 
Adult 12 275. 2±26. 2 160--474 
Piglet 18 565 . , 3±21. 4 263--740 
Neonate 21 408. . 4±19. , 8 254--562 
^Adult gilts and sows, 3 to 6 week old piglets and 
2 day old (neonatal) piglets. 
^SEM = Standard error of the mean. 
*Each age group differs significantly (P<0.05) from 
each other group. 
FIGURE 1. Typical adult pig aggregation tracings 
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TABLE 2. Platelet aggregation parameters in adult gilts and 
sows, 3 to 6 week old piglets and 2 day old 
(neonatal) piglets 
Aggregation Reagent 
Group 
Sodium 
aracnidonate 
(6.9 mM) 
ADP 
(20 mm) 
Collagen 
(10 Mg/ml) 
Adult 
Maximum aggregation (%) 
Slope (% change/min) 
Lag (seconds) 
Piglet 
Maximum aggregation (%) 
Slope (% change/min) 
Lag (seconds) 
Neonate 
Maximum aggregation (%) 
Slope (% change/min) 
Lag (seconds) 
89.4±3,6 32.4±2.9 
79.6+18.6 35.4±3.8 
80.7+3.6 44.4±2.9' 
185.9+18.6 63.0+3.8 
58.1±3.6' 37.4±2.9 
111.9+18.6 55.5 ±3.8' 
75.7+1.5 
71.6±4.1 
41.6±1.2 
81.5±1.5' 
105.7±4.l' 
3 7.7±1.2' 
73.0±1.5 
84.2±4.1' 
39.1±1.2 
Data are expressed as mean values ± the standard 
error of the mean. Each group consisted of 20 pigs. 
*The value differs significantly (P<0.05) from the 
adult value. 
FIGURE 2. Atypical neonatal piglet platelet aggregation 
tracing induced by 6.9 mM sodium arachidonate 
28  
20 
40 
60 
tS! 80 
Minutes 
2 3 
T T 
6.9 mM Sodium Arachidonate 
100'-
29 
collagen (Table 2). Only 2 of 20 piglets in this age group 
exhibited a reversible platelet aggregation response to the 
addition of sodium arachidonate. 
Mean cholesterol concentrations were higher in the 
neonatal serum (mean=101 mg/dl) than in either the adult 
gilt and sow (mean=80 mg/dl) or the 3 to 6 week old serums 
(mean=85 mg/dl). There were, however, no significant 
differences among the 3 groups. 
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DISCUSSION 
Reported porcine whole blood platelet numbers vary 
3-5 
markedly. Platelet numbers reported here correspond with 
reported values in miniature and Nigerian pigs.^'^ Platelet 
numbers increased from the relatively thrombocytheraic levels 
shortly after birth to the very high levels at weaning 
before decreasing to adult values. 
Newborn human infant platelets exhibit decreased 
responsiveness to ADP and collagen and no response to 
epinephrine. Arachidonic acid-induced platelet aggregation 
Q g 
in the human infant is comparable with that in adults. ' 
Similarly when the newborn foal is compared to the mare the 
newborn foal has reduced platelet responsiveness to ADP and 
collagen and a normal response to arachidonic acid. 
Epinephrine does not induce platelet aggregation in the 
foal, mare or pig.^^ 
In the present study the neonatal porcine platelet 
maximal aggregation response to ADP and collagen was not 
significantly different from that of the adult platelet. 
This suggests that the neonatal pig platelet is relatively 
more mature than either the human infant or the newborn foal 
platelet. The 3 to 6 week old porcine platelet appears to 
be relatively hyperaggregable when induced with ADP and 
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collagen. Diet has been reported to affect thrombus 
formation in pigs. in that study serum cholesterol had a 
significant positive correlation with thrombus formation in 
12 
an extracorporeal shunt. Diet was not controlled in this 
study but a retrospective evaluation of blood cholesterol 
values among the 3 age groups failed to reveal a significant 
difference. 
Platelet aggregation responses may be dependent on the 
plasma concentration of the anticoagulant which varies with 
13 
the packed cell volume. None of the pigs used in this 
study showed clinical evidence of anemia. Packed cell 
volumes were not measured in this study. 
Human platelet aggregation is apparently mediated by 2 
14 
or 3 interrelated pathways. In one of these pathways 
arachidonic acid, a cell membrane fatty acid, is mobilized 
in response to the action of a variety of agonists and 
rapidly converted by the cyclo-oxygenase enzyme complex to 
intermediate cyclic endoperoxides and then to thromboxane by 
thromboxane synthetase. Arachidonic acid metabolism in the 
human neonatal platelet differs from that of adults in that 
thromboxane formation is decreased while leukotriene 
formation through the alternative lipoxygenase pathway is 
increased. Increased release of substrate arachidonic acid 
from human neonatal platelet membranes counterbalances this 
32 
relative decrease in thromboxane formation so that the 
overall conversion of arachidonic acid to thromboxane is 
15 Similar in adult and neonatal platelets. In this study 
neonatal porcine platelets reacted one of two ways to sodium 
arachidonate. One group reacted similarly to adult gilts 
and sows with irreversible aggregation. The second group, 
however, exhibited a primary reversible aggregation 
response. This suggests that either thromboxane synthesis 
is imperfectly developed in neonatal pigs and that the 
aggregation response may be a direct action of sodium 
arachidonate (minimal nonspecific platelet lysis with the 
release of ADP) or due to an intermediate aggregatory 
prostaglandin (PGG2 and PGH2)-^^ 
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SUMMARY 
Four levels of aspirin treatment (0, 1, 20, 100 mg/kg) 
were given daily for 2 days to four groups of 5 piglets. 
Complete blood counts, clot retraction, factor VIII:related 
antigen concentration, bleeding time and platelet 
aggregation were measured 24 hours before the first and 24 
hours after the last aspirin treatment. 
Aspirin treatment did not significantly alter the cell 
counts, the degree of clot retraction, the concentration of 
factor VIII:related antigen or the bleeding time. Platelet 
aggregation induced by collagen was decreased with maximal 
suppression of platelet aggregation being evident in the 20 
mg/kg dosage group. Aggregation induced by adenosine 
diphosphate and high dose sodium arachidonate was not 
significantly changed by aspirin treatment. These 
observations suggest that aspirin does suppress platelet 
function in the pig but that the degree of suppression is 
mild. 
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INTRODUCTION 
Aspirin (acetylsalicylic acid) has been recommended as 
1 2 
an anti-inflammatory agent in animals including the pig. ' 
In addition to its analgesic and antipyretic properties 
aspirin irreversibly inhibits platelet function by 
acetylation of the cyclo-oxygenase complex thereby 
inhibiting the conversion of arachidonic acid to the 
prostaglandins and thromboxane.^ Aspirin inhibition of 
platelet function has been utilized in malignant 
4-8 hyperthermia and comparative vascular research in pigs. 
It has been demonstrated that the porcine platelet 
generates less thromboxane than equal numbers of human or 
c a n i n e  p l a t e l e t s  u n d e r  t h e  s a m e  s t i m u l a t i o n . T h i s  
suggests that aspirin may not be as potent an inhibitor of 
platelet function in pigs as in other species. 
This project will examine the effects of various 
dosages of oral aspirin on porcine platelet function. 
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MATERIALS AND METHODS 
Pigs-Twenty piglets (4 to 7 weeks old, 6 to 15 kgs) of 
either sex were used. These pigs are part of a pseudorabies 
and rhinitis free herd maintained indoors at Iowa State 
University. 
The piglets were evenly divided into 4 groups; a 
control group (no aspirin), a low dose group (1 rag/kg body 
weight for 2 consecutive days), a high dose group (20 mg/kg 
for 2 consecutive days) and a super-high dose group (100 
mg/kg for 2 consecutive days). 
Sample Collection-Piglets were anesthetized to allow 
for ease of venipunctures and bleeding time measurements. 
An intramuscular (IM) injection of azaperone^ (5 mg/kg) was 
followed 15-20 minutes later by an IM injection of ketamine^ 
(10 mg/kg). This combination provided 20-30 min of complete 
relaxation. 
Blood samples were obtained at 24 hours before oral 
aspirin administration^ (day 0) and again 24 hours after the 
second oral aspirin dose (day 3). Samples were collected 
from either the jugular vein or the carotid artery into 
evacuated tubes without anticoagulant (clot retraction) and 
into tubes containing EDTA (total and differential white 
blood cell counts, hemoglobin, packed cell volume and plasma 
protein, and platelet count). Blood for platelet 
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aggregation was collected from the same site into 
siliconized glass tubes containing 3.8% trisodium citrate at 
a ratio of 9 volumes of blood to 1 volume of anticoagulant. 
Platelet poor plasma (PPP) from this sample was stored 
frozen at -70° c until submission to the reference 
laboratory on dry ice for rocket immunoelectrophoretic 
determination of relative amounts of Factor VII I:related 
antigen. 
Following blood collection, a bleeding time was 
performed on anesthetized piglets using a commercial 
bleeding time device.® The bleeding time site used was the 
relatively hairless portion of the thoracic wall medial to 
the forelimb. 
An additional EDTA blood sample was collected from the 
cephalic vein of unanesthetized piglets 4 hours after 
ingestion of the second aspirin treatment. Plasma salicylate 
concentrations were determined by a colorimetric technique.^ 
Clot retraction-The degree of clot retraction was 
quantitatively evaluated by a modification of Rowsell's 
method.Whole blood was allowed to clot undisturbed in a 
corked siliconized glass tube at 37° C for 24 hours. The 
whole blood volume and the poured serum volume were measured 
in a graduated cylinder. The clot volume is the difference 
between these two measurements. The degree of clot 
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retraction was expressed as the per cent volume of clot to 
the total blood volume originally in the tube. 
Platelet Aggregation-This technique has been described 
elsewhere.^ In short, citrated whole blood was centrifuged 
(600 X g for 3.0 min at 20° c) to obtain platelet rich 
plasma (PRP). The PRP was diluted with autogenous PPP to 
obtain a working PRP with approximately 200,000 
platelets/Ml • Adenosine diphosphate^ (ADP, 20 juM) , 
collagen^ (5 and 10 Mg/ml) and sodium arachidonate^ (6.9 mM) 
were used as the aggregating agents. Platelet aggregation 
was recorded over a 5 min period using a multichannel 
analyzer. 
Parameters measured were the maximum % aggregation 
where PRP was set as 0% transmission and PPP was 100% 
transmission of light and the slope as the initial % change 
in transmittance per minute. The lag time between the 
addition of collagen and the point in which measurable 
aggregation had occurred was also measured. In addition, 
aggregation curves were examined for overall pattern. 
Statistics-All aggregations were performed in duplicate 
and the mean result calculated. Group data are expressed as 
the mean ± the standard error of the mean. An analysis of 
variance (ANOVA)^ or, where appropriate, an analysis of 
covariance (ANCOVA)^ was performed to detect group 
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differences. A significance level of 0.05 was maintained 
throughout the study. 
45 
RESULTS 
Overall hematologic values did not change significantly 
between day 0 and day 3 (Table 3). There was a significant 
difference in adjusted mean lymphocyte counts among the four 
treatment groups after aspirin treatment (P=0.045) but no 
clear trend was evident. 
Bleeding times, clot retraction and relative 
concentrations of Factor VII I:related antigen did not vary 
significantly among the 4 treatment groups either before or 
after aspirin treatment (Table 4). Mean plasma salicylate 
concentrations, four hours after the second oral dose of 
aspirin, varied significantly among the 4 groups. The high 
dose (mean plasma salicylate=3.27 mg/dl) and the super-high 
dose (mean=14.73 mg/dl) aspirin treatment groups were 
significantly different from the control group (mean=0.90 
mg/dl) and each other. The plasma salicylate concentration 
of the low dose aspirin group (mean=1.01 mg/dl) was not 
significantly different from that of the control group. 
Reversible ADP-induced platelet aggregation was not 
significantly altered by aspirin treatment (data not shown). 
The maximum % platelet aggregation induced by collagen 
was reduced by increasing doses of aspirin (Table 5). 
Maximal suppression of platelet aggregation was achieved 
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TABLE 3. Pooled hematologic data for 20 piglets before (day 
0) and after (day 3) oral aspirin treatment 
Day 0 Day 3 
PCV (%) 27.8+0.92^ 27.7+0.85 
Hemoglobin (g/dl) 8.6±0.31 8.4+0.36 
MCHC (g/dl) 31. 0±0.31 30.7±0.29 
WBC (number s / i U l )  90051453 7965+404 
Band Neutrophils (numbers/jul) 50±19 65±14 
Neutrophils (number s/jul ) 2673±258 21121194 
Lymphocytes (number s/jul ) 6065±310 56861250 
Monocytes (numbers/Ml) 115+22 43+11 
Eosinophils (numbers/^l) 62±17 38+12 
Basophils (numbers/Ml) 27±10 21+9 
nRBC (numbers/100 WBC) 0.15±0.11 0.1510.08 
Plasma Prot (g/dl) 4.4±0.09 4.410.07 
Fibrinogen (mg/dl) 200±14 205115 
Platelets (numbers x lO^/jul) 412±33 462123 
^Values expressed here as 
no significant differences (P<0 
the day 3 values. 
mean ± SEM, n=20. 
.05) between the 
There were 
day 0 and 
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TABLE 4. Bleeding times, clot retractions and plasma Factor 
VIII:related antigen concentrations in piglets 
before (day 0) and after (day 3) oral aspirin 
treatments 
Measurement Day 0 Day 3 
Bleeding Tirae^ (minutes) 
Control (0 mg/kg) l.6±0.5^ 2.2+0.5 
Low dose (1 mg/kg) l.5±0.2 2.5±0.5 
High dose (20 mg/kg) 2.1±0.5 3.0±0.4 
Super-high dose (100 mg/kg) 1.9±0.3 2.9±0.5° 
Clot Retraction^ (% clot/total blood volume) 
Control 25.5±3.1 24.0±2.g 
Low dose 24.0±2.5 24.2±3.0 
High dose 24.2±1.3 25.2+2.7 
Super-high dose 23.8±2.6 24.5±4.4 
Factor Vlllrrelated antigen^ (% normal reference pool) 
Control 86.0+10.5 79.6±7.2 
Low dose 93.4±5.1 83.2±4.7 
High dose 92.6±10.6 84.8±10.2 
Super-high dose 91.6±10.0 87.6±9.4 
^n=5. 
^The adjusted mean ± the standard error of the 
adjusted mean. P>0.05 for all tests. 
°One bleeding time was technically unsatisfactory and 
was excluded from the statistical analysis. 
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with the 20 mg/kg high dose treatment. Further suppression 
was not observed in the super-high dose treatment group. 
The lag phase preceding collagen-induced platelet 
aggregation and the initial rate of platelet aggregation 
(the slope) were not significantly altered by the aspirin 
treatments although a trend toward an increasing lag phase 
and a decreased rate of initial aggregation was evident. 
Aspirin treatment did not alter the monophasic irreversible 
nature of collagen-induced platelet aggregation. 
Sodium arachidonate induced either monophasic and 
biphasic waves of irreversible platelet aggregation which 
were not suppressed by aspirin treatment (data not shown). 
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TABLE 5. Maximum % platelet aggregation induced by 2 doses 
of collagen in piglets having received various 
amounts of oral aspirin 
Final collagen concentration 
Treatment group 5 u-g/ml' 10 fxg/ml 
Control (0 mg/kg) 
Low dose (1 mg/kg) 
High dose (20 mg/kg) 
Super-high dose (100 mg/kg) 
55.9±6.5 
48.9+6.9 
29.916.?' 
29.6+6.4' 
72.7±2.5 
69.2+3.0 
60.7±2.6' 
60.4+2.e' 
n = 4. 
'^ n = 5. 
^Values are expressed as the adjusted mean ± the 
standard error of the adjusted mean. 
*The mean treatment value is significantly different 
(P<0.05) from the corresponding mean control value. 
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DISCUSSION 
oral aspirin treatment in piglets did not alter the 
numbers of circulating platelets or decrease the ability of 
clotted blood to retract. 
Aspirin has been shown to increase the bleeding time in 
man^^ and horses^^'^^. Increased bleeding times were not 
observed in this study. A possible explanation is that the 
test, as it was performed, was not sensitive to detect the 
possible increase in bleeding time. An alternative 
explanation is based on the observation that collagen 
induced maximum platelet aggregation, while suppressed, was 
not less than 50% of the control value. This suggests that 
substantial platelet function was maintained. 
ADP induces only primary reversible platelet 
aggregation in the pig. Primary aggregation is reported to 
15 
not be inhibited by cyclo-oxygenase inhibitors. The 
results of this study support that observation. 
Aspirin has been shown to reduce arachidonic acid-
induced platelet aggregation in man^^ dogs^^ and cats^^. 
It has been indicated, however, that platelet aggregation 
induced by high concentrations of arachidonic acid is not 
mediated by intermediates of cyclo-oxygenase derived 
15 products. The results described in this report are 
consistent with the later observation. 
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This study suggests that aspirin does reduce porcine 
platelet function but this effect is much less pronounced in 
pigs when compared to other species including man. This is 
consistent with the relatively low amounts of thromboxane 
generated by stimulated porcine platelets. 
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SUMMARY 
Aspirin reduced the in vitro porcine platelet 
aggregation response to collagen. Two groups of piglets, an 
untreated control group and an oral aspirin pretreated 
group, received intravascular infusions of bovine tendon 
collagen. Although both groups had increased pulmonary 
vascular resistance and increased pulmonary arterial 
pressure following collagen infusions aspirin pretreatment 
significantly reduced the degree of response. 
The control piglet group became neutropenic following 
collagen infusion while the aspirin pretreated piglets 
showed no change in numbers of circulating neutrophils. 
Aspirin pretreatment, therefore, reduced the cardiovascular 
effects of intravascular collagen infusion but it is not 
clear if the cause of this reduction is platelet inhibition 
or decreased platelet-neutrophil interaction. 
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INTRODUCTION 
Collagen suspensions are commonly used to induce 
platelet aggregation in the laboratory. Aspirin 
(acetylsalicylic acid), an arachidonic pathway inhibitor, 
has been shown to reduce collagen-induced platelet 
aggregation in man^ and pigs.^ 
Upon aggregation platelets release a variety of 
biologically active substances that affect subsequently 
arriving cells, alter blood flow and affect the coagulation 
2 3 
cascade. ' The platelet response is further modified by 
4 intact vascular endothelium. Drugs that affect platelet 
aggregation in vitro therefore may not be effective in 
5 
vivo. 
The purpose of this experiment was to evaluate and 
compare the hematologic, respiratory and cardiovascular 
responses of aspirin treated and untreated control piglets 
subjected to an intravascular infusion of collagen. 
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MATERIALS AND METHODS 
Pigs-Eight piglets (6 to 7 weeks old, 13 to 17 kg) of 
either sex were used. These pigs are part of a pseudorabies 
and rhinitis free herd maintained indoors at the College of 
Veterinary Medicine, Iowa State University. 
Experimental design-The piglets were evenly divided 
into two groups: a control group (no aspirin) and an aspirin 
treatment group. The aspirin treatment group received oral 
aspirin, 20 mg/kg, once a day for 2 days with collagen 
challenge occurring approximately 24 hours after the second 
aspirin dosage. 
Collagen preparation-Bovine tendon collagen^ was 
suspended in sterile, endotoxin free Tyrode's salt solution^ 
as previously described.^ This suspension contained 
approximately 50 fig collagen/ml and was stored frozen at 
-70° C until used. Aliquots of the same collagen suspension 
were used in all piglets. 
Animal preparation-Each piglet was tranquilized with an 
intramuscular injection of acepromazine^ (5 mg/piglet) and 
allowed to rest undisturbed for 30-45 minutes. Anesthesia 
was induced by slow intravenous injection of thiamylal 
sodium^ to effect (approximately 8 mg/kg). Anesthesia was 
maintained by intermittent thiamylal sodium injections. 
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Cardiovascular and respiratory responses were collected 
using a multichannel physiograph recorder connected to a 
microcomputer for data analysis. This laboratory is 
7 described in detail elsewhere. 
The anesthetized piglets were placed in dorsal 
recumbency, a tracheostomy performed and a cuffed 
endotracheal tube tied in place. The endotracheal tube was 
attached to a pneumotach which in turn was attached to a 
differential transducer allowing the measurement of 
inspiratory and expiratory flow rates. The electronic 
integration of the pneumotach measurements gave a measure of 
air volume per respiratory cycle. 
Both femoral arteries and one femoral vein were 
isolated for cannulation. Two Swan-Ganz double-lumen 
thermodilution catheters® were used to cannulate a femoral 
vein and artery. The femoral vein catheter was advanced 
through the heart and into the pulmonary artery. This 
catheter was used for recording pressure changes in the 
pulmonary artery and for thermodilution determinations of 
cardiac output. The second catheter was advanced up the 
femoral artery to the aortic valve. The proximal port (30 
cm from the tip) was used to measure aortic pressure and 
heart (pulse) rate. The contralateral femoral artery was 
also cannulated and the cannula was stoppered with a 3-way 
valve providing ready access for arterial blood collection. 
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The pigs were heparinized (100 units/kg, intravenous 
injection) and allowed to lie undisturbed for at least 5 
minutes before baseline (time period 1) sampling. 
Measured respiratory parameters were tidal volume 
(ml/breath), respiratory rate (breaths/min) and minute 
volume (ml/min). Measured cardiovascular parameters were 
mean pulmonary arterial pressure (mmHg), mean systemic 
pressure (mmHg) and heart rate (pulses/min). Additionally 
8 thermodilution curves were obtained allowing the 
measurement of cardiac output (CO; ml/min), right 
ventricular stroke volume (ml/pulse), pulmonary vascular 
resistance (mmHg/ml-sec ^) and systemic vascular resistance 
(mmHg/ml-sec ^). 
Blood samples-Blood samples were collected into a 
variety of anticoagulants. Citrated plasma (9 volumes of 
blood to one volume of 3.8% citrate) was used for 
prothrombin time (PT), activated partial thromboplastin time 
(PTT) and factor VIII:related antigen (VIIIRrAg) 
determinations.^ EDTA anticoagulated whole blood was used 
for complete blood counts and platelet counts. Arterial 
blood gas and acid-base samples were collected anaerobically 
into heparinized syringes, corked, and stored under ice 
water until processed.^ All blood gas and acid-base 
determinations were made within an hour and a half of 
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collection. Additionally, blood was collected into a 
plastic syringe containing 3.8% trisodium citrate volume 
adjusted against the individual piglet's packed cell volume 
to give a final plasma citrate concentration of 15 mM. 
These samples were used in platelet aggregation studies as 
previously described.^ In this study platelets were 
challenged with commercial collagen^ (10 (xg/ml final 
concentration), an aliquot of the bovine tendon collagen 
used as an infusate (6 wg/ml), and adenosine diphosphate 
(ADP; 20 MM).^ 
Collagen infusions-The collagen suspension was slowly 
infused over 30 seconds into the femoral vein (0.44 ml/kg). 
This infusion was repeated twice more (see below). 
Sampling protocol-A citrated blood sample was collected 
before the piglet was heparinized and was used to determine 
preheparinization PT, PTT and VIIIR:Ag concentration. 
Cardio-pulmonary measurements were made at time l 
(baseline), time 2 (maximal systemic pressure response to 
collagen infusion I), time 3 (collagen I recovery, 
approximately 10 minutes after collagen infusion I), time 4 
(maximal response to collagen infusion II) and time 5 
(collagen II recovery, again approximately 10 minutes after 
collagen infusion). Notice that time 3 acts as a baseline 
measurement for comparison to time 4. Blood samples were 
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drawn simultaneously with the cardio-pulmonary measurements 
but not all possible blood samples were collected at each 
time period (Table 6). 
After the time 5 samples were collected the pig was 
given a final collagen infusion (collagen infusion III) and 
then euthanized with an intravenous injection of 
barbiturates at the maximal systemic vascular pressure 
response. A routine post mortem examination was performed. 
The lungs were collected within 15 minutes following 
euthanasia and perfused, intratracheally, with 10% neutral 
buffered formalin at 30 cm water pressure. The lungs were 
allowed to fix in the formalin solution for a minimum of 1 
day. Lung samples from the dorsal aspect of the cranial and 
caudal lung lobes, both left and right sides, were 
dehydrated in graded alcohols, embedded in paraffin, 
sectioned at 5 nm and stained with hematoxylin and eosin. 
Statistical analysis-The piglets were divided into 4 
blocks. Each block contained a pair of piglets, one from 
each of the two treatment groups. The data were evaluated 
by the use of the analysis of variance using a general 
linear model (PROC GLM).^ The overall experimental design 
was considered a split plot design where aspirin treatment 
formed the whole block factor and time was the split plot 
factor. In addition selected least significant differences 
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TABLE 6 Blood sample collection protocol 
Time 
period^ 
Platelet 
count 
CBC Blood gas 
& 
acid-base 
Platelet 
aggregation 
PT, PTT 
& 
VIIIR:Ag 
1 + + + + + 
2 + - + - -
3 + - + - -
4 + - + - -
5 + + + - + 
^See text for explanation. 
between groups within a time period (LSD^) and between time 
periods for a group (LSD2) were calculated and are included 
in the appropriate figure titles. Platelet aggregations 
were performed in duplicate and the mean result was 
calculated. Since aggregation profiles were determined once 
for each animal the analysis was a simple randomized block 
design. 
Data are expressed as the mean and the mean ± the 
standard error of the mean. A significance level of P<0.05 
was maintained throughout the study. 
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RESULTS 
Platelet aggregation-Aspirin treatment significantly 
reduced the maximum platelet aggregation response to both 10 
and 6 ixq/vxl collagen suspensions. The initial rate of 
aggregation (slope) and the lag time between the addition of 
collagen and detectable platelet aggregation were not 
affected by aspirin treatment. Platelet response to ADP was 
not significantly affected by aspirin treatment (Table 7). 
Hematology-Mean platelet counts decreased after both 
collagen infusions for both aspirin treated piglets and 
controls but, due to the wide variation of the standard 
error of the mean platelet count, this decrease was not 
statistically significant (P=0.09, 1 and 24 degrees of 
freedom: Figure 3). 
Total leukocyte numbers decreased significantly for 
both groups across the entire experiment. Lymphocyte 
numbers decreased while band neutrophil numbers increased 
slightly. The most dramatic change was the decrease in 
circulating numbers of mature segmented neutrophils. The 
control group's mean neutrophil count dropped from 
3,953±538/m1 (time 1) to 1,710±199/#1 (time 5). Aspirin 
treated piglets, however, showed only a slight, 
statistically insignificant, decrease from a mean segmented 
neutrophil count of 4,02311,449/^1 to 3,73811,954/^1-
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TABLE 7. The effect of aspirin (20 mg/kg) on porcine 
platelet aggregation 
Commercial Collagen 
Aggregation collagen infusate ADP 
parameter (10 txq/ml) (6 #g/ml) (20 juM) 
Maximal aggregation (% aggregation) 
Control group 84 . 0^ 58 .8 50 . 5 
Aspirin treated 
* 
68 . 3 55 . 3 * 48 . 8 
Slope (initial % aggregation/min) 
Control group 85 . 8 59 . 0 61. 2 
Aspirin treated 00
 
00
 
54 . 8 67 . 2 
Lag phase (seconds) 
Control group 35 60 NA^ 
Aspirin treated 34 59 NA 
^Each value represents the mean result of four animals. 
'^NA = not applicable. 
*The value differs significantly (P<0.05) from the 
control group's corresponding value. 
Packed cell volumes and hemoglobin, plasma protein and 
fibrinogen concentrations did not change significantly 
during the course of the experiment. 
Acid-base and blood gases-There was no significant 
change in the blood pH or the partial pressure of carbon 
FIGURE 3. Mean arterial platelet counts, 4 piglets per 
treatment group. Samples were taken at time 
1 (baseline), time 2 (maximal systemic pressure 
response to collagen infusion I), time 3 
(collagen I recovery, approximately 10 minutes 
after collagen infusion), time 4 (maximal 
response to collagen infusion II) and time 5 
(collagen II recovery, again approximately 10 
minutes after collagen infusion). Least 
significant difference (P<0.05) between 
treatment groups within a time period (LSDi) 
is 149. Least significant difference (P<0.05) 
between time periods for a treatment group 
(LSDg) is 132 
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dioxide either between groups or across the duration of the 
experiment. The arterial PO2, however, dropped 
significantly for both groups following collagen infusions 
and showed an overall significant downward trend across the 
duration of the experiment- There was no significant 
difference between aspirin treated and untreated control 
piglets (Figure 4). 
Respiratory parameters-There were no significant 
changes in tidal volume, respiratory rate or minute volume 
between groups or due to collagen infusion. 
Cardiovascular parameters- The most obvious response to 
repeated collagen infusions was a marked transient decrease 
in systemic vascular pressure. Baseline mean systemic 
pressures were significantly greater in aspirin treated 
piglets than in control animals. There was, however, no 
significant difference between the two groups in their 
response to collagen infusion (Figure 5). 
Mean systemic vascular resistance rose significantly in 
both of the treatment groups fallowing the first collagen 
infusion (time 2) and never returned to baseline values. 
Mean pulmonary arterial pressure in the control piglets 
also increased significantly following the first collagen 
infusion and also never returned to baseline pressures. 
Aspirin treated piglets also had a rise in pulmonary 
FIGURE 4. Mean arterial partial pressure of oxygen, 4 
piglets per treatment group. LSD^=16.4. 
LSD2=9.6. See figure 3 for an 
explanation of the time periods and the 
abbreviations 
Mean Arterial Partial Pressure 
of Oxygen (mm Hg) 
FIGURE 5. Systemic arterial mean pressure, 4 piglets per 
treatment group. LSDj_ = 10.3. LSD2 = 11.0. 
See figure 3 for an explanation of the time 
periods and abbreviations 
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arterial pressure but this rise was significantly less than 
in the controls (Figure 5). 
Pulmonary vascular resistance and heart rate increased 
significantly in control piglets following the first 
collagen infusion while aspirin treated piglets showed a 
lesser change. Pulmonary vascular resistance in aspirin 
treated piglets rose slightly (Figure 7) while heart rate 
did not change significantly. 
There were no significant changes in stroke volume or 
cardiac output between the groups or following collagen 
infusion. 
Coagulation times and factor VII I:related antigen 
concentration-Heparin infusion did not alter the FT or the 
VlllR:Ag concentration. The overall mean PTT for both 
groups increased from 17.9 to 29.4 sec five minutes after 
intravenous heparin injection (time 1). Neither the PT nor 
the PTT changed over the course of the experiment (from time 
1 to time 5). Factor VII I:related antigen, however, showed 
a significant 31% increase during the course of the 
experiment. 
Post mortem examinations-All piglets showed a diffuse 
purplish discoloration of the dorsal aspects of all lung 
lobes. This discoloration was markedly decreased when the 
lungs were expanded with formalin. No gross lesions were 
identified in the remainder of the carcasses. 
FIGURE 6. Pulmonary arterial mean pressure, 4 piglets per 
treatment group. LSD2=12.7 LSD2=5.5. 
See figure 3 for an explanation of the time 
periods and the abbreviations 
Pulmonary Arterial Mean Pressure 
(mm Hg) 
FIGURE 7. Pulmonary vascular resistance, 4 piglets per 
treatment group. LSD2=0.48. LSD2=0.16. 
See figure 3 for an explanation of the time 
periods and the abbreviations 
Pulmonary Vascular Resistance 
(mm Hg/ml/second) 
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The microscopic appearance of the lungs from the 
aspirin treatment group was compared to the appearance of 
the lungs from the untreated control piglet group. The 
control group had a diffuse, primarily neutrophilic, 
cellular infiltrate in the walls of the pulmonary alveoli 
(Figure 8) and increased numbers of intravascular platelet 
microaggregates (Figure 9) . These intravascular platelet 
aggregates contained relatively large numbers of 
neutrophils; many more than expected in proportion to the 
numbers of erythrocytes. One piglet in the control group 
who had suffered iatrogenic laryngeal hemorrhage before the 
tracheostomy, had small numbers of erythrocytes free in the 
alveolar lumina. 
FIGURE 8. (Top) Lung, from an aspirin pretreated 
piglet following 3 intravascular infusions 
of bovine tendon collagen. Hematoxylin 
and eosin; x 158 
FIGURE 8. (Bottom) Lung, from an untreated control 
piglet following 3 intravascular infusions 
of bovine tendon collagen. There are 
increased numbers of neutrophils and mono­
nuclear cells in the walls of the alveoli 
throughout the section and a moderately 
sized platelet aggregate in the lumen of the 
vein in the center of the photograph. 
Hematoxylin and eosin; x 158 
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FIGURE 9. Lung, from an untreated control piglet 
following 3 intravascular infusions of 
bovine tendon collagen. There is a 
large platelet aggregate with moderate 
numbers of erythrocytes and neutrophils 
in the lumen of the large vein in the 
center of the photograph. The 
surrounding alveoli are hypercellular. 
(See figure 8.) Hematoxylin and 
eosin; x 62 
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DISCUSSION 
Aspirin inhibits platelet aggregation by irreversibly 
acetylating the cyclo-oxygenase enzyme thereby inhibiting 
the conversion of arachidonic acid to thromboxane. Aspirin 
also inhibits the formation of prostacyclin from arachidonic 
acid by vascular endothelial cells. 
In this study aspirin decreased collagen-induced ex 
vivo maximum % platelet aggregation. This correlates well 
with previous work in piglets^ and suggests that arachidonic 
acid metabolites have a role in porcine platelet 
aggregation. 
Intravascular collagen injection causes platelet 
aggregation and a decrease in circulating platelet counts in 
9-16 
cats, dogs, rabbits, guinea-pigs and rats. In the 
guinea-pig the decrease in platelet count is collagen dose 
dependent with only a transient decrease in platelet counts 
/ 14 being seen in the 30 #g/kg treatment group. 
In this study platelet counts decreased following 
collagen infusion but this decrease was not statistically 
significant. Part of the reason for this may be due to the 
very low concentrations of collagen used in this experiment 
(26 iug/kg) . A low collagen dose was used for a variety of 
reasons. The most important reason is that high dose 
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collagen-induced aggregation is independent of arachidonic 
17 
acid metabolism and aspirin inhibition. Additional causes 
for the lack of a significant decrease in platelet numbers 
may be small sample size and occasional marked variations in 
platelet counts in the same piglet. This individual 
variation may be the result of splenic contraction with the 
18 
mobilization of large stores of platelets. 
Collagen-induced intravascular platelet aggregation has 
been used to induce cardio-pulmonary injury.Expected 
cardiovascular changes are increased pulmonary arterial 
pressure, decreased or normal cardiac output, increased 
pulmonary vascular resistance and decreased systemic 
9.19 
arterial pressure. These changes also occurred in this 
study. Systemic vascular resistance increased suggesting 
that not all of the vasoactive platelet microaggregates 
localized in the lung but that some occured in the systemic 
vasculature. This combination of pulmonic and systemic 
platelet microaggregates following collagen infusion has 
14 been demonstrated in the guinea-pig. 
There is no ready explanation why baseline systemic 
arterial pressures should be greater in aspirin treated 
piglets than in untreated controls. 
Leukopenia, decreased fibrinogen concentrations and 
decreased complement activity have been found in dogs 
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19 following intravascular collagen injection. In this study 
we also noted a significant leukopenia. Both groups became 
lymphopenia. Lymphopenias are commonly associated with a 
stress response in animals. More importantly, control 
piglets had a marked drop in numbers of circulating mature 
neutrophils. Neutrophil numbers did not significantly 
decrease in aspirin treated animals. Since aspirin is 
reported to have no effect on complement-induced granulocyte 
2 0 
aggregation in cats it is doubtful that aspirin inhibited 
the neutropenia by interfering with that mechanism. 
Platelets can modify neutrophil function in other ways. 
Thromboxane, a potent constrictor of arteriolar smooth 
muscle induces platelet aggregation and is the major active 
metabolite of platelet arachidonic acid metabolism. 
Thromboxane also mediates increased polymorphonuclear 
leukocyte adhesiveness. Indomethacin, an inhibitor of 
arachidonic acid metabolism, reduced augmented human 
21 polymorphonuclear leukocyte adherence to nylon. Platelet 
derived growth factor, a constituent of the platelet a 
granule, acts as a strong chemoattractant for neutrophils, 
increases neutrophil aggregation and has been shown to 
2 2 2 3 increase neutrophil adherence to plastic surfaces. ' 
24 
Aspirin will inhibit platelet a granule release thereby 
theoretically decreasing platelet derived growth factor 
release and neutrophil function. 
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The gross discoloration of the dorsal aspects of the 
lungs in all of the piglets may be attributed to both 
atelectasis and hypostatic congestion. These changes are 
most likely secondary to the animals being placed in a 
supine position for the duration of the experiment and they 
provide a reasonable explanation for the slow decrease in 
the arterial partial pressure of oxygen observed in both 
treatment groups. The neutropenic untreated control group 
had increased numbers of neutrophils in the walls of the 
pulmonary alveoli strongly suggesting that circulating 
neutrophils were sequestered in the lungs. The observation 
that relatively increased numbers of neutrophils are present 
in platelet aggregates lends morphologic support to a 
possible platelet-neutrophil interaction. 
VIIIR:Ag can be found in plasma, platelets, 
megakaryocytes and endothelial cells. Increased 
concentration of this antigen in the plasma has been 
associated with vascular diseases in man and is reported to 
have originated with increased release from endothelial 
cells. The origin of the increase in VIIIRrAg was not 
identified in this study. 
In summary, aspirin pretreatment moderated the 
increases in mean pulmonary arterial pressure, pulmonary 
vascular resistance and heart rate as well as decreases in 
90 
circulating segmented neutrophil numbers. It was beyond the 
scope of this study to investigate whether the protectant 
effect was a direct action of aspirin on platelet function 
or a result of decreased piatelet-neutrophil interactions. 
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GENERAL SUMMARY AND DISCUSSION 
When a blood vessel is damaged a complex series of 
events called the hemostatic mechanism is initiated. 
Platelets interact with plasma von Willebrand factor and 
exposed subendothelial structures to form the initial 
hemostatic plug. Following shape change and primary 
aggregation platelets release their granule contents. The 
dense granules contain adenine nucleotides, amines and 
divalent cations which together amplify platelet responses 
and cause vasoconstriction. The more numerous a granules 
contain antiheparin and coagulant proteins, fibronectin, 
growth factor(s) and von Willebrand factor. Platelet 
membrane arachidonic acid is liberated and rapidly 
metabolized to a variety of prostaglandins and the potent 
aggrgating agent thromboxane A2. Platelet recruitment and 
aggregation continues until an adequate platelet mass has 
formed over the site of damage . ^ ^ ^ 
Platelet dysfunction can be quantitative or 
qualitative, primary or secondary, inherited or acquired. 
In man and the horse normal neonatal platelets exhibit 
reduced responsiveness to collagen and adenosine diphosphate 
4 4 " 4 6 (ADP). The cause of this normal age related variation 
is not known but it is thought to be a relative defect in 
97 
45 
either a membrane receptor or phospholipase A2. Neonatal 
piglet platelets, however, respond to collagen and ADP as 
well as or even more vigorously than sow and mature gilt 
platelets suggesting that the neonatal porcine platelet is 
relatively more mature at birth than human or equine 
platelets. 
Porcine platelets do not aggregate at concentrations of 
arachidonic acid that cause irreversible platelet 
aggregation in man. The suggested explanation is that 
alternative arachidonic-independent platelet activation 
pathways are relatively more important in the basic porcine 
109 
platelet response. Higher doses of arachidonic acid cause 
5 3 platelet aggregation in rats and pigs (Matthews, 
Department of Veterinary Pathology, ISU, unpublished data) 
but this aggregation is apparently independent of cyclo-
oxygenase derived products. Interestingly, high dose sodium 
arachidonate did not cause irreversible aggregation in 8 of 
20 neonatal piglets. The reason for this is not known but 
it appears to be a defect in the direct action of 
arachidonic acid on platelet function. It has been shown 
that arachidonic acid will covalently bind to intact human 
platelet proteins independent from both cyclo-oxygenase and 
lipoxygenase activity. 
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Aspirin inhibits human platelet function by inhibiting 
the enzyme cyclo-oxygenase. Pig platelets have a relatively 
poor ability to generate thromboxane when stimulated by 
either thrombin or collagen.This would suggest that 
cyclo-oxygenase inhibition by aspirin would have little 
physiological consequence in the pig. In spite of this 
aspirin was one of the best platelet function inhibitors 
tested in pigs following balloon angioplasty. 
Our results indicate that aspirin does affect porcine 
platelet function, particularly the aggregation response 
initiated by low dose collagen. This in vitro inhibition 
appears to be relatively mild and can be partially overcome 
by increasing the concentration of the collagen used to 
initiate aggregation. These findings are consistent with 
112 the observations made on aspirin treated human platelets. 
The in vivo response to intravascular collagen infusion 
is consistent with the in vitro findings. Aspirin 
pretreatment did not prevent the vascular response to the 
infusion but the response was attenuated. More surprising 
was the fact that aspirin prevented the neutropenia found in 
the untreated control animals. Perhaps the clinical 
importance of aspirin therapy in the pig will lie not with 
the ability of aspirin to inhibit platelet cyclo-oxygenase 
but with the ability of aspirin to decrease platelet 
interactions with other mediators of inflammation. 
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APPENDIX A 
Sodium arachidonate-induced porcine platelet aggregation 
Introduction 
Human, feline, canine, equine, bovine and porcine 
platelets all possess an arachidonate pathway and generate 
thromboxane, however, bovine and porcine platelets do not 
aggregate when stimulated by 0.5 mM arachidonate.^ 
Porcine platelet aggregation apparently is induced by 
2 6.9mM sodium arachidonate. It could be argued that platelet 
aggregation tracings following high dose arachidonate 
stimulation represent platelet lysis rather than platelet 
aggregation. 
Gross examination of aggregation cuvettes after 5 
minutes of 6.9 mM sodium arachidonate-induced aggregation 
revealed macroaggregates of platelets suggesting that at 
least some platelets were still intact. Stronger evidence 
that 6.9 mM sodium arachidonate does not cause significant 
platelet lysis during the 5 minutes that platelet 
aggregation is being monitored can be found in careful 
examination of reversible sodium arachidonate-induced 
platelet aggregation tracings. The tracings show that the 
final turbidity (5 rain) is back to the baseline platelet 
l i a  
rich plasma value. Platelet lysis would produce an 
irreversible change in turbidity. 
This project was designed to further investigate the 
possibility that high dose arachidonate causes platelet 
lysis rather than aggregation by examining the concentration 
of lactate dehydrogenase (LDH) found in the plasma after 
platelet aggregation. 
Materials and methods 
Part A-Seven sets of aggregation cuvettes were prepared 
in duplicate with 450 (xl of platelet rich plasma 
(PRP:200,000 platelets/]Ltl) being placed into each of 4 sets 
of cuvettes and 450 ixl of platelet poor plasma (PPP) being 
added to the remaining 3 sets. Routine platelet aggregation 
was initiated in one set of cuvettes with 50 Ml of collagen^ 
(10 ng/ml). A collagen control was prepared by adding an 
identical amount of the same collagen suspension to a set of 
PPP cuvettes. Similarly platelet aggregation was induced 
t) 
with 6.9 mM sodium arachidonate in PRP. An arachidonate 
control in PPP was also prepared. One set of PRP and one 
set of PPP cuvettes were left undisturbed. Finally, in an 
attempt to lyse platelets, one set of PRP cuvettes were 
frozen (-20° C) and thawed 3 times in succession. 
All of the cuvettes were simultaneously centrifugea, 
the supernatant citrated plasmas collected, labeled with a 
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code number and submitted to the veterinary clinical 
pathology laboratory for routine determination of LDH 
activity. The time lapse from the addition of arachidonate 
to the PRP cuvettes and the collection of plasma was 
approximately 40 minutes. 
Part B-Four additional 450 til cuvettes were prepared. 
These cuvettes were placed into a centrifuge and collagen 
was added to one set of cuvettes while arachidonate was 
added to the other set. The samples were spun for 5 minutes 
and the plasma was then harvested. These plasma samples 
were labeled with a code number and submitted to the 
clinical pathology laboratory for LDH activity 
determination. This submission was separate from the Part A 
submission and was analyzed by the lab the following work 
day. 
Results 
The results of the LDH assays are in Table 8. 
Part A-The addition of collagen and sodium arachidonate 
did not increase the plasma LDH activity of the PPP over the 
basal PPP LDH activity. This shows that there was no 
significant LDH activity in either one of the platelet 
agonists. 
LDH activity did not differ between the untreated PRP 
sample and the PPP sample. 
1 2 0  
Both collagen aggregation and 3 cycle freeze-thawing 
did not increase the plasma LDH activity. A 40 minute 
exposure of PRP to 6.9 mM sodium arachidonate did result in 
a marked increase in plasma LDH activity. 
Part B-A 5 minute incubation of PRP with sodium 
arachidonate did not significantly increase the plasma LDH 
activity over parallel collagen and PRP incubation. 
Discussion 
Lactate dehydrogenase is found in the cytoplasm of 
cells.^ Cell membrane damage and cell necrosis cause leakage 
of this enzyme from the cell into the surrounding plasma. 
It appears that prolonged incubation of porcine platelets 
with relatively high concentrations of sodium arachidonate 
will cause cell membrane damage but little to no detectable 
platelet damage occurs during the first 5 minutes after the 
addition of sodium arachidonate to the PRP, the time period 
when platelet aggregation is evaluated. 
Based on physical examination, turbidity measurements 
and enzyme assays it appears that 6.9 mM sodium arachidonate 
does not lyse porcine platelets during the first 5 minutes 
of platelet aggregation. 
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TABLE 8. LDH activity following platelet aggregation 
Cuvette LDH activity^ 
Part A: 
Part BI 
PPP^ 154 
PPP+collagen 140 
PPP+arachidonate 144 
PRP° 160 
PRP+collagen 153 
PRP+arachidonate 328 
PRP freeze-thawed 143 
PRP+collagen 111 
PRP+arachidonate 117 
^Lactate dehydrogenase activities (international 
units/liter) are expressed as the mean of 2 determinations. 
"^Platelet poor plasma. 
"^Platelet rich plasma. 
•Lettered footnotes 
a. Helena Laboratories, Beaumont, TX. 
b. Sigma Chemical Co., St. Louis, MO. 
1 2 2  
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APPENDIX B 
Salicylic acid concentrations in porcine plasma 
Introduction 
A commercial kit for the quantitative, colorimetric 
determination of serum and plasma salicylic acid 
concentration was purchased for use in a porcine research 
project. Before it was used, however, the ability of this 
test to accurately determine salicylic acid concentrations 
in porcine plasma was evaluated. 
Materials and methods 
Sample preparation-A commercial kit used to determine 
salicylic acid concentrations in human serum and plasma^ and 
a series of salicylic acid standards^ (12, 25, 50 and 100 
mg/dl) were purchased. Five piglets were bled from the 
jugular vein or carotid artery into evacuated tubes 
containing EDTA. Plasma was obtained by centrifugation of 
the anticoagulated blood samples and pooled. 
Experimental design-The design of this experiment 
follows the original work in human serum and urine by 
Trinder.^ A series of plasma samples with known salicylate 
concentrations was obtained by mixing equal volumes of 
pooled plasma with each of the salicylate standards. A 
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plasma blank was prepared by mixing equal volumes of pooled 
plasma with distilled water. These prepared samples were 
then routinely processed for determination of salicylate 
concentrations following the manufacturer's directions. The 
% recovery was calculated as the mean of observed 
concentrations minus the plasma blank concentration and then 
divided by the expected value. 
% recovery= [ (mean observed - blank) 4- expected] x 100% 
Results 
The results are presented in Table 9. The coefficient 
of variation at the 7.5 and the 12.5 mg/dl salicylate 
concentrations were 2.4 and 2.7% respectively. 
Discussion 
This colorimetric test for the determination of 
salicylate concentrations in plasma is simple, rapid (5 
minutes/sample) and provides reproducible results. This 
test appears applicable to salicylic acid determinations in 
porcine EDTA plasma. 
•Lettered footnote 
a. Sigma Chemical Co., St. Louis, Mo., USA. 
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TABLE 9. Recovery of salicylic acid added to porcine plasma 
Salicylic acid 
added (mg/dl) 
Number of 
samples 
Mean 
(mg/dl) 
Recovery^ 
(%) 
0 2 0.35 • • • • 
7 . 5 4 7 . 80 99 . 3 
12.5 4 12 . 70 98 . 8 
25.0 2 25 .51 100 . 6 
50 . 0 2 48 .26 95 . 8 
^r=0.999. 
Reference 
1. Trinder P. Rapid determination of salicylate in 
biological fluids. BÎOChem J 19 54;57:301-303. 
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APPENDIX C 
The in vitro effects of aspirin and sodium salicylate on 
porcine platelet aggregation 
Introduction 
Aspirin (acetylsalicylic acid) in a humid environment 
gradually hydrolyzes to salicylic and acetic acids.^ The 
half-life of aspirin in the blood of man is 15-20 minutes 
while the half-life of the metabolite salicylic acid is 4-5 
2 hours. 
Pigs receiving oral aspirin have a depressed collagen-
3 induced maximal platelet aggregation response. 
The purpose of this study was to examine the effects of 
aspirin and sodium salicylate on maximal % platelet 
aggregation induced by various doses of collagen and high 
dose (6.9 mM) sodium arachidonate. 
Materials and methods 
Sample preparation-Blood was collected from two mature 
gilts belonging to a herd maintained indoors at the College 
of Veterinary Medicine, Iowa State University. The blood 
was collected into plastic syringes containing 3.8% 
trisodium citrate as 9 volumes of blood to 1 volume of 
citrate. Platelet rich plasma (PRP) and platelet poor 
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plasma was prepared as described previously.^ Platelet 
aggregations were performed in duplicate and the mean 
maximal % aggregation was calculated. Aspirin^ (molecular 
weight=180.15) was dissolved in sterile normal saline 
(pH=5.5) to provide a 4.5 mM stock solution. (This provided 
a final aspirin concentration of 500 MM in the FRF). 
Dilutions were made of the aspirin stock to provide PR? 
final aspirin concentrations of 250, 100 and 50 juM. 
Salicylic acid, sodium salt^ (molecular weight=160.1) was 
also dissolved in sterile normal saline to provide a 2.25 liK 
stock solution which then provided a 250 mM final sodium 
salicylate concentration in the PRP. Both salicylate stock 
solutions were prepared the morning of the experiment and 
used within 2-5 hours of preparation. The PRP (400 nl; 
approximately 220,000 platelets/Ml) was incubated with 50 Ml 
of saline or one of the concentrations of salicylate for 3 
minutes at 37° C before aggregation was begun. Platelet 
aggregating agents were collagen^, 5 or 10 fxg/ml or 5.9 mM 
sodium arachidonate.^ Platelet aggregation was monitored and 
maximal platelet aggregation within the first 5 minutes 
after the addition of the aggregating agent was recorded. 
1 2 8  
Results 
Aspirin, at all levels, markedly reduced 5 ixg/ml 
collagen-induced platelet aggregation. Aspirin suppression 
of 10 ng/ml collagen-induced platelet aggregation was 
obvious but less dramatic. Sodium salicylate did not 
suppress collagen-induced platelet aggregation (Table 10). 
Neither aspirin or sodium salicylate suppressed sodium 
arachidonate induced platelet aggregation (Table 11). 
TABLE 10. Collagen-induced platelet aggregation 
Inhibitor 5 txq/ral collagen 
Gilt A Gilt B 
10 jug/ml collagen 
Gilt A Gilt B 
Normal saline 
64.6 
Aspirin (jUM) 
50 20.5 
100 19.0 
250 16.1 
500 22.8 
Sodium salicylate (juM) 
250 73.3 
6 2 . 6  
2 2 . 6  
21.2 
18.8 
18.4 
61. 4 
75 . 8 
68 . 8 
55 . 9 
53.8 
54.8 
77 . 2 
74.4 
53.8 
53 . 8 
43 . 9 
47 . 2 
77 . 2 
^Maximal % aggregation, mean of 2 runs. 
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TABLE 11. Sodium arachidonate-induced platelet aggregation 
Inhibitor 6.9 mM sodium arachidonate 
Gilt A Gilt B 
Normal saline 
23.4^ 87.8 
Aspirin (/uM) 
250 13.4 87.3 
Sodium salicylate (mM) 
250 15.4 87.7 
^Maximal % aggregation, mean of 2 runs. 
Discussion 
These results have an excellent correlation with 
"^pYe vT"o u" "sT y "de se ri bed "effects of aspirin on porcine platelet 
aggregation.^ The degree of suppression of collagen-induced 
aggregation is greater in vitro than in vivo. This was not 
unexpected. 
Aspirin treatment, in vivo, would rapidly produce a 
mixture of acetylsalicylic acid and salicylic acid. In rats 
oral aspirin dosing resulted in peak aspirin concentrations 
immediately after administration. After only 5 minutes 
plasma salicylic acid concentrations were 20 times greater 
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4 than aspirin concentrations. In man, approximately 60% of 
absorbed ingested aspirin is converted to salicylic acid in 
5 
the first pass through the liver. Salicylic acid then 
2 interferes with the platelet inhibitory effects of aspirin. 
The difference in the timing of the aspirin treatments 
between the in vivo and in vitro experiments may have played 
a role in the difference in degree of inhibition but this is 
unlikely. In man inhibition of platelet prostaglandin 
synthesis persists for approximately 48 hours after a single 
dose of aspirin^suggesting that oral aspirin inactivates 
megakaryocyte cyclo-oxygenase as well as irreversibly 
7 inhibits platelet cyclo-oxygenase. 
Suppression of collagen-induced platelet aggregation 
was more evident at the lower concentration of collagen. In 
man collagen concentrations greater than 2 ug/ml can bring 
about the platelet reaction without activation of the 
p 
arachidonic acid pathway. The results presented here would 
suggest that this is also true for the pig. 
I do not know why gilt A was hyporesponsive to 
arachidonic acid-induced platelet aggregation. One 
possibility is that these aggregations were performed last 
and some loss of platelet function may have occurred. This 
seems unlikely since gilt B, run in parallel, did not 
exhibit this decrease in reactivity. Another possibility is 
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that I inadvertently contaminated gilt A's PRP pool with a 
small amount of an aggregation agent after the collagen-
induced platelet aggregation study. This also seems 
unlikely since the pipette tips for the PRP were different 
than those used for the aggregating agents and I could not 
have easily misused one in place of the other. 
High dose arachidonic acid-induced platelet aggregation 
was not inhibited in pigs given oral aspirin.^ The results 
of this limited study would support this in that neither 
aspirin or sodium salicylate appeared to inhibit "normal" 
sodium arachidonate-induced platelet aggregation, 
Indomethacin, another common cyclo-oxygenase inhibitor, did 
not inhibit 6 mM arachidonic acid-induced platelet 
9 
aggregation in rats. The author of this study concluded 
that arachidonic acid, at this high level, directly 
triggered the platelet release reaction. 
In summary, in vitro platelet inhibition by aspirin 
strongly supports the previous report on the effects of oral 
aspirin on porcine platelet aggregation. 
Lettered footnotes 
a. Sigma Chemical Co., St. Louis, Mo. 
b. Helena Laboratories, Beaumont, Tx. 
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